Effect of ischemic time on pediatric heart transplantation outcomes: is it the same for all allografts?


Journal

Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574

Informations de publication

Date de publication:
06 2022
Historique:
revised: 02 02 2022
received: 27 09 2021
accepted: 15 02 2022
pubmed: 9 3 2022
medline: 12 5 2022
entrez: 8 3 2022
Statut: ppublish

Résumé

Studies have shown that the optimal ischemia time (IT) threshold in pediatric heart transplantation (PHT) is up to 4 h, independent of other donor organ factors. The purpose of this study was to examine the relationship between IT and donor left ventricular ejection fraction (LVEF) and study their impact on PHT outcomes. This is a retrospective cohort study of PHT (<18 years) identified in UNOS between January 2000 and March 2020. Post-transplantation survival analysis of patients receiving donor hearts with IT<4, 4-6, and >6 h was performed using Kaplan-Meier curves. Cohort was divided according to donor LVEF median value, and survival was analyzed. Cox regression was performed. Median LVEF was 65% in the study cohort (6669 PHT). Overall, IT>6 h was associated with worse survival compared to <4 h regardless of donor LVEF. For allografts with LVEF < 65%, IT = 4-6 h was associated with worse survival compared with IT < 4 h (p = .006) but had similar survival compared with IT > 6 h (p = .315). For allografts with LVEF ≥ 65%, IT = 4-6 h had similar survival compared with <4 h (p = .175) but improved survival compared with >6 h (p = .003). After adjusting for donor and recipient variables, Cox regression showed that IT = 4-6 h was not associated with increased mortality for LVEF ≥ 65%. The IT threshold of 4 h does not apply to all allografts. Recipients of hearts with LVEF≥65% can tolerate an IT up to 6 h without any detriment to survival. Routine acceptance of these donor hearts could mitigate longer waiting times and poor donor availability for many candidates.

Sections du résumé

BACKGROUND
Studies have shown that the optimal ischemia time (IT) threshold in pediatric heart transplantation (PHT) is up to 4 h, independent of other donor organ factors. The purpose of this study was to examine the relationship between IT and donor left ventricular ejection fraction (LVEF) and study their impact on PHT outcomes.
METHODS
This is a retrospective cohort study of PHT (<18 years) identified in UNOS between January 2000 and March 2020. Post-transplantation survival analysis of patients receiving donor hearts with IT<4, 4-6, and >6 h was performed using Kaplan-Meier curves. Cohort was divided according to donor LVEF median value, and survival was analyzed. Cox regression was performed.
RESULTS
Median LVEF was 65% in the study cohort (6669 PHT). Overall, IT>6 h was associated with worse survival compared to <4 h regardless of donor LVEF. For allografts with LVEF < 65%, IT = 4-6 h was associated with worse survival compared with IT < 4 h (p = .006) but had similar survival compared with IT > 6 h (p = .315). For allografts with LVEF ≥ 65%, IT = 4-6 h had similar survival compared with <4 h (p = .175) but improved survival compared with >6 h (p = .003). After adjusting for donor and recipient variables, Cox regression showed that IT = 4-6 h was not associated with increased mortality for LVEF ≥ 65%.
CONCLUSIONS
The IT threshold of 4 h does not apply to all allografts. Recipients of hearts with LVEF≥65% can tolerate an IT up to 6 h without any detriment to survival. Routine acceptance of these donor hearts could mitigate longer waiting times and poor donor availability for many candidates.

Identifiants

pubmed: 35258159
doi: 10.1111/petr.14259
pmc: PMC9159355
mid: NIHMS1807097
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14259

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL147957
Pays : United States

Informations de copyright

© 2022 Wiley Periodicals LLC.

Références

Pediatr Transplant. 2021 May;25(3):e13912
pubmed: 33245837
J Heart Lung Transplant. 2011 Nov;30(11):1244-9
pubmed: 21676628
J Heart Lung Transplant. 2005 Jan;24(1):58-62
pubmed: 15653380
Pediatr Transplant. 2019 Aug;23(5):e13417
pubmed: 31081171
J Heart Lung Transplant. 2019 Oct;38(10):1028-1041
pubmed: 31548029
J Heart Lung Transplant. 2020 Mar;39(3):241-247
pubmed: 31874793
J Heart Lung Transplant. 2014 Oct;33(10):996-1008
pubmed: 25242124
J Heart Lung Transplant. 2017 Oct;36(10):1060-1069
pubmed: 28779892
Transl Pediatr. 2019 Oct;8(4):284-289
pubmed: 31728321
J Heart Lung Transplant. 2020 Oct;39(10):1028-1037
pubmed: 32773323
Pediatr Transplant. 2020 May;24(3):e13671
pubmed: 32198830
Circulation. 2002 Sep 24;106(12 Suppl 1):I163-7
pubmed: 12354727

Auteurs

Alia Dani (A)

Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Quyen Vu (Q)

Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Karthik Thangappan (K)

Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Bin Huang (B)

Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Samuel Wittekind (S)

Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Angela Lorts (A)

Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Clifford Chin (C)

Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

David L S Morales (DLS)

Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Farhan Zafar (F)

Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH